首页 > 最新文献

Frontiers in Cardiovascular Medicine最新文献

英文 中文
Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors 治疗心房颤动的抗凝剂:从华法林和 DOACs 到 XI 因子抑制剂的前景
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1352734
Vineet Kumar, Leonard Ilkhanoff
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose have evolved significantly over the past decades with the aim of optimizing effectiveness while minimizing bleeding risks. Though significant improvements have been made toward this goal, bleeding risk remains the major concern with these therapies. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism. This mini-review will discuss anticoagulants currently used for stroke prevention in patients with atrial fibrillation including warfarin and direct oral anticoagulants. We will also review the mechanism of action and data from early clinical trials for Factor XI inhibitors and discuss their potential advantages and shortcomings.
抗凝是合适的心房颤动患者预防中风的主要方法。由于药物疗法的进步,过去几十年来,用于这一目的的抗凝药物有了很大发展,目的是在最大限度降低出血风险的同时优化疗效。尽管在实现这一目标方面取得了重大进展,但出血风险仍然是这些疗法的主要问题。在临床前和早期临床试验中,一类抑制因子 XI 的试验用药已显示出有望在保持抗中风和全身性栓塞疗效的同时显著降低出血风险。本微型综述将讨论目前用于预防心房颤动患者中风的抗凝剂,包括华法林和直接口服抗凝剂。我们还将回顾因子 XI 抑制剂的作用机制和早期临床试验数据,并讨论其潜在的优势和不足。
{"title":"Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors","authors":"Vineet Kumar, Leonard Ilkhanoff","doi":"10.3389/fcvm.2024.1352734","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1352734","url":null,"abstract":"Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose have evolved significantly over the past decades with the aim of optimizing effectiveness while minimizing bleeding risks. Though significant improvements have been made toward this goal, bleeding risk remains the major concern with these therapies. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism. This mini-review will discuss anticoagulants currently used for stroke prevention in patients with atrial fibrillation including warfarin and direct oral anticoagulants. We will also review the mechanism of action and data from early clinical trials for Factor XI inhibitors and discuss their potential advantages and shortcomings.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"10 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139802840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
So close, yet so far away: the relationship between MAM and cardiac disease 如此之近,却又如此之远:MAM 与心脏病之间的关系
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1353533
Bo Lu, Xiaozhe Chen, Yulong Ma, Mingtai Gui, Lei Yao, Jianhua Li, Mingzhu Wang, Xunjie Zhou, D. Fu
Mitochondria-associated membrane (MAM) serve as crucial contact sites between mitochondria and the endoplasmic reticulum (ER). Recent research has highlighted the significance of MAM, which serve as a platform for various protein molecules, in processes such as calcium signaling, ATP production, mitochondrial structure and function, and autophagy. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health. Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. MAM proteins independently or interact with their counterparts, forming essential tethers between the ER and mitochondria in cardiomyocytes. This review provides an overview of key MAM regulators, detailing their structure and functions. Additionally, it explores the connection between MAM and various cardiac injuries, suggesting that precise genetic, pharmacological, and physical regulation of MAM may be a promising strategy for preventing and treating heart failure.
线粒体相关膜(MAM)是线粒体和内质网(ER)之间的重要接触点。最近的研究突显了线粒体相关膜在钙信号传导、ATP生成、线粒体结构和功能以及自噬等过程中的重要性,因为线粒体相关膜是各种蛋白质分子的平台。任何原因引起的心脏病都会导致心肌结构和功能发生变化,严重影响人类健康。值得注意的是,在肥胖、糖尿病和心脏毒性等几种心脏疾病中,MAM 表现出多种调节作用,以维持细胞平衡。MAM 蛋白独立或与对应蛋白相互作用,在心肌细胞的 ER 和线粒体之间形成重要的纽带。本综述概述了主要的 MAM 调控因子,详细介绍了它们的结构和功能。此外,它还探讨了 MAM 与各种心脏损伤之间的联系,认为对 MAM 进行精确的遗传、药物和物理调控可能是预防和治疗心衰的一种有前途的策略。
{"title":"So close, yet so far away: the relationship between MAM and cardiac disease","authors":"Bo Lu, Xiaozhe Chen, Yulong Ma, Mingtai Gui, Lei Yao, Jianhua Li, Mingzhu Wang, Xunjie Zhou, D. Fu","doi":"10.3389/fcvm.2024.1353533","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1353533","url":null,"abstract":"Mitochondria-associated membrane (MAM) serve as crucial contact sites between mitochondria and the endoplasmic reticulum (ER). Recent research has highlighted the significance of MAM, which serve as a platform for various protein molecules, in processes such as calcium signaling, ATP production, mitochondrial structure and function, and autophagy. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health. Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. MAM proteins independently or interact with their counterparts, forming essential tethers between the ER and mitochondria in cardiomyocytes. This review provides an overview of key MAM regulators, detailing their structure and functions. Additionally, it explores the connection between MAM and various cardiac injuries, suggesting that precise genetic, pharmacological, and physical regulation of MAM may be a promising strategy for preventing and treating heart failure.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"6 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139806202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block 病例报告:使用有源固定导联进行临时起搏和侵入性电生理学研究治疗免疫检查点抑制剂相关的可逆性晚期房室传导阻滞
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1336609
Yifan Wang, Min Qian, Xiaofeng Jin, Jiaqi Wang, Tai-bo Chen, Peng Gao, Zhongwei Cheng, Jinzhi Lai, Yongtai Liu, Jingbo Fan, Lihua Zhang, Kangan Cheng, H. Deng, Quan Fang, Deyan Yang
A case of immune checkpoint inhibitors (ICIs)-associated myocarditis with reversible advanced atrioventricular block (AVB) was reported. We innovatively used active fixation lead connected to an external device for prolonged temporary pacing until atrioventricular conduction recovered. Invasive electrophysiology studies were performed to evaluate atrioventricular conduction in detail. Long-term follow-up for nearly 120-days and repeated long-term electrocardiography was conducted to ensure the conduction system was truly recovered.
报告了一例免疫检查点抑制剂(ICIs)相关心肌炎伴可逆性晚期房室传导阻滞(AVB)的病例。我们创新性地使用了与外部装置相连的有源固定导联进行长时间临时起搏,直至房室传导恢复。我们进行了有创电生理学研究,以详细评估房室传导。进行了近 120 天的长期随访和反复的长期心电图检查,以确保传导系统真正恢复。
{"title":"Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block","authors":"Yifan Wang, Min Qian, Xiaofeng Jin, Jiaqi Wang, Tai-bo Chen, Peng Gao, Zhongwei Cheng, Jinzhi Lai, Yongtai Liu, Jingbo Fan, Lihua Zhang, Kangan Cheng, H. Deng, Quan Fang, Deyan Yang","doi":"10.3389/fcvm.2024.1336609","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1336609","url":null,"abstract":"A case of immune checkpoint inhibitors (ICIs)-associated myocarditis with reversible advanced atrioventricular block (AVB) was reported. We innovatively used active fixation lead connected to an external device for prolonged temporary pacing until atrioventricular conduction recovered. Invasive electrophysiology studies were performed to evaluate atrioventricular conduction in detail. Long-term follow-up for nearly 120-days and repeated long-term electrocardiography was conducted to ensure the conduction system was truly recovered.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"54 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139864203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors 治疗心房颤动的抗凝剂:从华法林和 DOACs 到 XI 因子抑制剂的前景
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1352734
Vineet Kumar, Leonard Ilkhanoff
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose have evolved significantly over the past decades with the aim of optimizing effectiveness while minimizing bleeding risks. Though significant improvements have been made toward this goal, bleeding risk remains the major concern with these therapies. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism. This mini-review will discuss anticoagulants currently used for stroke prevention in patients with atrial fibrillation including warfarin and direct oral anticoagulants. We will also review the mechanism of action and data from early clinical trials for Factor XI inhibitors and discuss their potential advantages and shortcomings.
抗凝是合适的心房颤动患者预防中风的主要方法。由于药物疗法的进步,过去几十年来,用于这一目的的抗凝药物有了很大发展,目的是在最大限度降低出血风险的同时优化疗效。尽管在实现这一目标方面取得了重大进展,但出血风险仍然是这些疗法的主要问题。在临床前和早期临床试验中,一类抑制因子 XI 的试验用药已显示出有望在保持抗中风和全身性栓塞疗效的同时显著降低出血风险。本微型综述将讨论目前用于预防心房颤动患者中风的抗凝剂,包括华法林和直接口服抗凝剂。我们还将回顾因子 XI 抑制剂的作用机制和早期临床试验数据,并讨论其潜在的优势和不足。
{"title":"Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors","authors":"Vineet Kumar, Leonard Ilkhanoff","doi":"10.3389/fcvm.2024.1352734","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1352734","url":null,"abstract":"Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose have evolved significantly over the past decades with the aim of optimizing effectiveness while minimizing bleeding risks. Though significant improvements have been made toward this goal, bleeding risk remains the major concern with these therapies. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism. This mini-review will discuss anticoagulants currently used for stroke prevention in patients with atrial fibrillation including warfarin and direct oral anticoagulants. We will also review the mechanism of action and data from early clinical trials for Factor XI inhibitors and discuss their potential advantages and shortcomings.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"160 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139862742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical effect of vein of Marshall ethanol infusion on mitral isthmus ablation 马歇尔静脉乙醇输注对二尖瓣峡部消融术的临床效果
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1253554
Weili Ge, Yi-Fei Lu, Tao Li, Ye Wang, Jie Yin, Xin-Ran Li, Jian-Jun Jiang, Ya-Fei Mi, Tao-Hsin Tung, Su-Hua Yan
This study aimed to investigate the effect of Marshall ethanol infusion (VOM-Et) in the vein on mitral isthmus (MI) ablation.Patients with persistent atrial fibrillation (AF) were grouped into vein of VOM-Et combined with radiofrequency (RF) ablation (VOM-Et-RF) and RF groups. The primary outcome was MI block immediate block rate after surgery. Stratified analysis was also performed for factors affecting the outcome measures.A total of 118 consecutive patients underwent AF ablation at Taizhou Hospital of Zhejiang Province from January 2018 to December 2021. Successful bidirectional perimitral block was achieved in 96% of patients in VOM-Et-RF (69 of 72) and in 76% of patients in the RF group (35 of 46) (P < 0.01). In the subgroup analysis, male sex, elder than 60 years, Left atrial diameter <55 mm, and AF duration <3 years were associated with the benefits of VOM-Et in AF Patients.The vein of Marshall ethanol infusion for catheter ablation can improve the MI block rate. Male sex, elder age, smaller Left atrial diameter and shorter AF duration may have significant benefits for VOM-Et.
本研究旨在探讨静脉输注马歇尔乙醇(VOM-Et)对二尖瓣峡部(MI)消融术的影响。持续性房颤(AF)患者被分为静脉VOM-Et联合射频(RF)消融术组(VOM-Et-RF)和射频组。主要结果是术后MI阻滞即刻阻滞率。2018年1月至2021年12月,共有118名连续患者在浙江省台州医院接受了房颤消融术。VOM-Et-RF组96%的患者(72例中的69例)和RF组76%的患者(46例中的35例)获得了成功的双向窦周阻滞(P<0.01)。在亚组分析中,男性、60 岁以上、左心房直径小于 55 毫米、房颤持续时间小于 3 年与房颤患者使用 VOM-Et 的益处相关。男性、高龄、较小的左心房直径和较短的房颤持续时间可能对 VOM-Et 有明显的益处。
{"title":"Clinical effect of vein of Marshall ethanol infusion on mitral isthmus ablation","authors":"Weili Ge, Yi-Fei Lu, Tao Li, Ye Wang, Jie Yin, Xin-Ran Li, Jian-Jun Jiang, Ya-Fei Mi, Tao-Hsin Tung, Su-Hua Yan","doi":"10.3389/fcvm.2024.1253554","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1253554","url":null,"abstract":"This study aimed to investigate the effect of Marshall ethanol infusion (VOM-Et) in the vein on mitral isthmus (MI) ablation.Patients with persistent atrial fibrillation (AF) were grouped into vein of VOM-Et combined with radiofrequency (RF) ablation (VOM-Et-RF) and RF groups. The primary outcome was MI block immediate block rate after surgery. Stratified analysis was also performed for factors affecting the outcome measures.A total of 118 consecutive patients underwent AF ablation at Taizhou Hospital of Zhejiang Province from January 2018 to December 2021. Successful bidirectional perimitral block was achieved in 96% of patients in VOM-Et-RF (69 of 72) and in 76% of patients in the RF group (35 of 46) (P < 0.01). In the subgroup analysis, male sex, elder than 60 years, Left atrial diameter <55 mm, and AF duration <3 years were associated with the benefits of VOM-Et in AF Patients.The vein of Marshall ethanol infusion for catheter ablation can improve the MI block rate. Male sex, elder age, smaller Left atrial diameter and shorter AF duration may have significant benefits for VOM-Et.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"33 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139866034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of miRNA-29c in the carotid plaque and its association with diabetic mellitus 颈动脉斑块中 miRNA-29c 的表达及其与糖尿病的关系
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1276066
Hua Wang, Peipei Mai, Fang He, Yanfang Zhang
Carotid artery atherosclerosis is a major cause of ischemic stroke, and ischemic stroke is the leading cause of morbidity and mortality worldwide. Unfortunately, the reason for the build-up of atherosclerosis plaque is unknown. The miRNA-29c was reported to promote the phenotype transformation of vascular smooth muscle cells (VSMCs) in diabetes mice, eventually leading to plaque formation and bleeding. However, such studies are rare and limited to animal experiments.In our study, 40 patients were divided into a diabetic mellitus (DM) group and a non-DM group according to whether they were diagnosed with DM. Then, the real-time quantitative PCR was applied to examine the miRNA-29c level in human carotid plaque tissue derived from 40 subjects receiving carotid endarterectomy.Briefly, diabetes patients had a decreased miRNA-29c level as compared with non-DM subjects, and this comparison was statistically significant (P = 0.02). Notably, variable miRNA-29c level was negatively associated with HbA1c level, although no statistical significance was observed. Moreover, there was an increased miRNA-29c level in patients with cerebral stroke.Collectively, the miRNA-29c level in the carotid plaque is closely associated with DM and cerebral stroke, which may contribute to atherosclerosis formation.
颈动脉粥样硬化是缺血性中风的主要原因,而缺血性中风是全球发病率和死亡率的主要原因。遗憾的是,动脉粥样硬化斑块堆积的原因尚不清楚。据报道,miRNA-29c 能促进糖尿病小鼠血管平滑肌细胞(VSMC)的表型转化,最终导致斑块形成和出血。在我们的研究中,40 名患者根据是否确诊为糖尿病(DM)分为糖尿病组和非糖尿病组。简单地说,与非糖尿病组相比,糖尿病患者的miRNA-29c水平有所下降,这种比较具有统计学意义(P = 0.02)。值得注意的是,不同的 miRNA-29c 水平与 HbA1c 水平呈负相关,但没有统计学意义。总之,颈动脉斑块中的 miRNA-29c 水平与 DM 和脑卒中密切相关,可能有助于动脉粥样硬化的形成。
{"title":"Expression of miRNA-29c in the carotid plaque and its association with diabetic mellitus","authors":"Hua Wang, Peipei Mai, Fang He, Yanfang Zhang","doi":"10.3389/fcvm.2024.1276066","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1276066","url":null,"abstract":"Carotid artery atherosclerosis is a major cause of ischemic stroke, and ischemic stroke is the leading cause of morbidity and mortality worldwide. Unfortunately, the reason for the build-up of atherosclerosis plaque is unknown. The miRNA-29c was reported to promote the phenotype transformation of vascular smooth muscle cells (VSMCs) in diabetes mice, eventually leading to plaque formation and bleeding. However, such studies are rare and limited to animal experiments.In our study, 40 patients were divided into a diabetic mellitus (DM) group and a non-DM group according to whether they were diagnosed with DM. Then, the real-time quantitative PCR was applied to examine the miRNA-29c level in human carotid plaque tissue derived from 40 subjects receiving carotid endarterectomy.Briefly, diabetes patients had a decreased miRNA-29c level as compared with non-DM subjects, and this comparison was statistically significant (P = 0.02). Notably, variable miRNA-29c level was negatively associated with HbA1c level, although no statistical significance was observed. Moreover, there was an increased miRNA-29c level in patients with cerebral stroke.Collectively, the miRNA-29c level in the carotid plaque is closely associated with DM and cerebral stroke, which may contribute to atherosclerosis formation.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139805417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overexpression of VEGFα as a biomarker of endothelial dysfunction in aortic tissue of α-GAL-Tg/KO mice and its upregulation in the serum of patients with Fabry’s disease α-GAL-Tg/KO小鼠主动脉组织中作为内皮功能障碍生物标志物的VEGFα过表达及其在法布里氏病患者血清中的上调作用
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1355033
N. Lund, H. Wieboldt, L. Fischer, N. Muschol, F. Braun, T. Huber, D. Sorriento, G. Iaccarino, K. Müllerleile, E. Tahir, G. Adam, P. Kirchhof, L. Fabritz, M. Patten
Fabry's disease is an X-linked lysosomal storage disorder caused by reduced activity of α-galactosidase A (GAL), leading to premature death on account of renal, cardiac, and vascular organ failure. Accumulation of the GAL substrate globotriaosylceramide (Gb3) in endothelial and smooth muscle cells is associated with early vascular cell damage, suggesting endothelial dysfunction as a driver of cardiorenal organ failure. Here, we studied the vascular expression of the key angiogenic factors, VEGFα and its antagonist angiostatin, in Fabry α-GAL-Tg/KO mice and determined circulating VEGFα and angiostatin serum levels in patients with Fabry’s disease and healthy controls.Cryopreserved aortic vessels from six α-GAL-Tg/KO and six wild-type (WT) mice were obtained and VEGFα and angiostatin levels were determined by performing Western blot analysis. VEGFα expression was visualized by an immunohistochemical staining of paraffin aortic rings. In addition, VEGFα and angiostatin serum levels were measured by using an enzyme-linked immunosorbent assay in 48 patients with genetically verified Fabry's disease (50% male) and 22 healthy controls and correlated with disease severity markers such as lyso-Gb3, albuminuria, NTproBNP, high-sensitive troponin T (hsTNT), and myocardial wall thickness.It was found that there was a significant increase in VEGFα protein expression (1.66 ± 0.35 vs. 0.62 ± 0.16, p = 0.0009) and a decrease in angiostatin expression (0.024 ± 0.007 vs. 0.053 ± 0.02, p = 0.038) in aortic lysates from α-GAL-Tg/KO compared with that from WT mice. Immunohistochemical staining revealed an adventitial VEGFα signal in α-GAL-Tg/KO mice, whereas no VEGFα signal could be detected in WT mice aortas. No differences in aortic angiostatin expression between α-GAL-Tg/KO- and WT mice could be visualized. The serum levels of VEGFα were significantly upregulated in patients with Fabry’s disease compared with that in healthy controls (708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml, p = 0.048) and positively associated with albuminuria (r = 0.82, p < 0.0001) and elevated NTproBNP (r = 0.87, p < 0.0001) and hsTNT values (r = 0.41, p = 0.048) in male patients with Fabry’s disease. For angiostatin, no significant difference was found between patients with Fabry’s disease and healthy controls (747.6 ± 390.3 vs. 858.8 ± 599.3 pg/ml).In conclusion, an overexpression of VEGFα and downregulation of its counter player angiostatin in aortic tissue of α-GAL-Tg/KO mice support the hypothesis of an underlying vasculopathy in Fabry's disease. Elevated VEGFα serum levels were also observed in patients with Fabry’s disease and were positively associated with elevated markers of organ manifestation in males. These findings suggest that angiogenetic markers, such as VEGFα, may be potentially useful biomarkers for the detection of endothelial dysfunction in classical Fabry's disease.
法布里病是一种 X 连锁溶酶体贮积症,由 α-半乳糖苷酶 A(GAL)活性降低引起,会导致肾脏、心脏和血管器官衰竭而过早死亡。内皮细胞和平滑肌细胞中 GAL 底物葡糖基甘油三酯(Gb3)的积累与早期血管细胞损伤有关,这表明内皮功能障碍是心肾器官衰竭的一个驱动因素。在此,我们研究了法布里α-GAL-Tg/KO小鼠血管中关键血管生成因子VEGFα及其拮抗剂血管抑素的表达,并测定了法布里病患者和健康对照组的循环VEGFα和血管抑素血清水平。通过对石蜡主动脉环进行免疫组化染色来观察 VEGFα 的表达。此外,还采用酶联免疫吸附法测定了 48 名经基因验证的法布里病患者(50% 为男性)和 22 名健康对照者的 VEGFα 和血管生长抑素血清水平,并将其与溶菌酶-Gb3、白蛋白尿、NTproBNP、高敏肌钙蛋白 T(hsTNT)和心肌壁厚度等疾病严重程度指标进行了相关分析。研究发现,与 WT 小鼠相比,α-GAL-Tg/KO 小鼠主动脉裂解物中 VEGFα 蛋白表达量明显增加(1.66 ± 0.35 vs. 0.62 ± 0.16,p = 0.0009),血管抑素表达量减少(0.024 ± 0.007 vs. 0.053 ± 0.02,p = 0.038)。免疫组化染色显示,α-GAL-Tg/KO 小鼠的主动脉内有血管内皮生长因子α信号,而 WT 小鼠的主动脉内检测不到血管内皮生长因子α信号。α-GAL-Tg/KO-小鼠和 WT 小鼠的主动脉血管生成素表达没有差异。与健康对照组相比,法布里病患者血清中的 VEGFα 水平明显升高(708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml,p = 0.048),并与白蛋白尿(r = 0.82,p < 0.0001)和法布里病男性患者的 NTproBNP(r = 0.87,p < 0.0001)和 hsTNT 值升高(r = 0.41,p = 0.048)呈正相关。总之,α-GAL-Tg/KO 小鼠主动脉组织中血管内皮生长因子α的过度表达及其对抗因子血管抑素的下调支持了法布里病潜在血管病变的假说。在法布里病患者血清中也观察到血管内皮生长因子α水平升高,并且与男性器官表现标志物升高呈正相关。这些研究结果表明,血管生成标记物(如 VEGFα)可能是检测典型法布里病内皮功能障碍的潜在有用生物标记物。
{"title":"Overexpression of VEGFα as a biomarker of endothelial dysfunction in aortic tissue of α-GAL-Tg/KO mice and its upregulation in the serum of patients with Fabry’s disease","authors":"N. Lund, H. Wieboldt, L. Fischer, N. Muschol, F. Braun, T. Huber, D. Sorriento, G. Iaccarino, K. Müllerleile, E. Tahir, G. Adam, P. Kirchhof, L. Fabritz, M. Patten","doi":"10.3389/fcvm.2024.1355033","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1355033","url":null,"abstract":"Fabry's disease is an X-linked lysosomal storage disorder caused by reduced activity of α-galactosidase A (GAL), leading to premature death on account of renal, cardiac, and vascular organ failure. Accumulation of the GAL substrate globotriaosylceramide (Gb3) in endothelial and smooth muscle cells is associated with early vascular cell damage, suggesting endothelial dysfunction as a driver of cardiorenal organ failure. Here, we studied the vascular expression of the key angiogenic factors, VEGFα and its antagonist angiostatin, in Fabry α-GAL-Tg/KO mice and determined circulating VEGFα and angiostatin serum levels in patients with Fabry’s disease and healthy controls.Cryopreserved aortic vessels from six α-GAL-Tg/KO and six wild-type (WT) mice were obtained and VEGFα and angiostatin levels were determined by performing Western blot analysis. VEGFα expression was visualized by an immunohistochemical staining of paraffin aortic rings. In addition, VEGFα and angiostatin serum levels were measured by using an enzyme-linked immunosorbent assay in 48 patients with genetically verified Fabry's disease (50% male) and 22 healthy controls and correlated with disease severity markers such as lyso-Gb3, albuminuria, NTproBNP, high-sensitive troponin T (hsTNT), and myocardial wall thickness.It was found that there was a significant increase in VEGFα protein expression (1.66 ± 0.35 vs. 0.62 ± 0.16, p = 0.0009) and a decrease in angiostatin expression (0.024 ± 0.007 vs. 0.053 ± 0.02, p = 0.038) in aortic lysates from α-GAL-Tg/KO compared with that from WT mice. Immunohistochemical staining revealed an adventitial VEGFα signal in α-GAL-Tg/KO mice, whereas no VEGFα signal could be detected in WT mice aortas. No differences in aortic angiostatin expression between α-GAL-Tg/KO- and WT mice could be visualized. The serum levels of VEGFα were significantly upregulated in patients with Fabry’s disease compared with that in healthy controls (708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml, p = 0.048) and positively associated with albuminuria (r = 0.82, p < 0.0001) and elevated NTproBNP (r = 0.87, p < 0.0001) and hsTNT values (r = 0.41, p = 0.048) in male patients with Fabry’s disease. For angiostatin, no significant difference was found between patients with Fabry’s disease and healthy controls (747.6 ± 390.3 vs. 858.8 ± 599.3 pg/ml).In conclusion, an overexpression of VEGFα and downregulation of its counter player angiostatin in aortic tissue of α-GAL-Tg/KO mice support the hypothesis of an underlying vasculopathy in Fabry's disease. Elevated VEGFα serum levels were also observed in patients with Fabry’s disease and were positively associated with elevated markers of organ manifestation in males. These findings suggest that angiogenetic markers, such as VEGFα, may be potentially useful biomarkers for the detection of endothelial dysfunction in classical Fabry's disease.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"128 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139862677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of miRNA-29c in the carotid plaque and its association with diabetic mellitus 颈动脉斑块中 miRNA-29c 的表达及其与糖尿病的关系
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1276066
Hua Wang, Peipei Mai, Fang He, Yanfang Zhang
Carotid artery atherosclerosis is a major cause of ischemic stroke, and ischemic stroke is the leading cause of morbidity and mortality worldwide. Unfortunately, the reason for the build-up of atherosclerosis plaque is unknown. The miRNA-29c was reported to promote the phenotype transformation of vascular smooth muscle cells (VSMCs) in diabetes mice, eventually leading to plaque formation and bleeding. However, such studies are rare and limited to animal experiments.In our study, 40 patients were divided into a diabetic mellitus (DM) group and a non-DM group according to whether they were diagnosed with DM. Then, the real-time quantitative PCR was applied to examine the miRNA-29c level in human carotid plaque tissue derived from 40 subjects receiving carotid endarterectomy.Briefly, diabetes patients had a decreased miRNA-29c level as compared with non-DM subjects, and this comparison was statistically significant (P = 0.02). Notably, variable miRNA-29c level was negatively associated with HbA1c level, although no statistical significance was observed. Moreover, there was an increased miRNA-29c level in patients with cerebral stroke.Collectively, the miRNA-29c level in the carotid plaque is closely associated with DM and cerebral stroke, which may contribute to atherosclerosis formation.
颈动脉粥样硬化是缺血性中风的主要原因,而缺血性中风是全球发病率和死亡率的主要原因。遗憾的是,动脉粥样硬化斑块堆积的原因尚不清楚。据报道,miRNA-29c 能促进糖尿病小鼠血管平滑肌细胞(VSMC)的表型转化,最终导致斑块形成和出血。在我们的研究中,40 名患者根据是否确诊为糖尿病(DM)分为糖尿病组和非糖尿病组。简单地说,与非糖尿病组相比,糖尿病患者的miRNA-29c水平有所下降,这种比较具有统计学意义(P = 0.02)。值得注意的是,不同的 miRNA-29c 水平与 HbA1c 水平呈负相关,但没有统计学意义。总之,颈动脉斑块中的 miRNA-29c 水平与 DM 和脑卒中密切相关,可能有助于动脉粥样硬化的形成。
{"title":"Expression of miRNA-29c in the carotid plaque and its association with diabetic mellitus","authors":"Hua Wang, Peipei Mai, Fang He, Yanfang Zhang","doi":"10.3389/fcvm.2024.1276066","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1276066","url":null,"abstract":"Carotid artery atherosclerosis is a major cause of ischemic stroke, and ischemic stroke is the leading cause of morbidity and mortality worldwide. Unfortunately, the reason for the build-up of atherosclerosis plaque is unknown. The miRNA-29c was reported to promote the phenotype transformation of vascular smooth muscle cells (VSMCs) in diabetes mice, eventually leading to plaque formation and bleeding. However, such studies are rare and limited to animal experiments.In our study, 40 patients were divided into a diabetic mellitus (DM) group and a non-DM group according to whether they were diagnosed with DM. Then, the real-time quantitative PCR was applied to examine the miRNA-29c level in human carotid plaque tissue derived from 40 subjects receiving carotid endarterectomy.Briefly, diabetes patients had a decreased miRNA-29c level as compared with non-DM subjects, and this comparison was statistically significant (P = 0.02). Notably, variable miRNA-29c level was negatively associated with HbA1c level, although no statistical significance was observed. Moreover, there was an increased miRNA-29c level in patients with cerebral stroke.Collectively, the miRNA-29c level in the carotid plaque is closely associated with DM and cerebral stroke, which may contribute to atherosclerosis formation.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"47 1-2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139865262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overexpression of VEGFα as a biomarker of endothelial dysfunction in aortic tissue of α-GAL-Tg/KO mice and its upregulation in the serum of patients with Fabry’s disease α-GAL-Tg/KO小鼠主动脉组织中作为内皮功能障碍生物标志物的VEGFα过表达及其在法布里氏病患者血清中的上调作用
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1355033
N. Lund, H. Wieboldt, L. Fischer, N. Muschol, F. Braun, T. Huber, D. Sorriento, G. Iaccarino, K. Müllerleile, E. Tahir, G. Adam, P. Kirchhof, L. Fabritz, M. Patten
Fabry's disease is an X-linked lysosomal storage disorder caused by reduced activity of α-galactosidase A (GAL), leading to premature death on account of renal, cardiac, and vascular organ failure. Accumulation of the GAL substrate globotriaosylceramide (Gb3) in endothelial and smooth muscle cells is associated with early vascular cell damage, suggesting endothelial dysfunction as a driver of cardiorenal organ failure. Here, we studied the vascular expression of the key angiogenic factors, VEGFα and its antagonist angiostatin, in Fabry α-GAL-Tg/KO mice and determined circulating VEGFα and angiostatin serum levels in patients with Fabry’s disease and healthy controls.Cryopreserved aortic vessels from six α-GAL-Tg/KO and six wild-type (WT) mice were obtained and VEGFα and angiostatin levels were determined by performing Western blot analysis. VEGFα expression was visualized by an immunohistochemical staining of paraffin aortic rings. In addition, VEGFα and angiostatin serum levels were measured by using an enzyme-linked immunosorbent assay in 48 patients with genetically verified Fabry's disease (50% male) and 22 healthy controls and correlated with disease severity markers such as lyso-Gb3, albuminuria, NTproBNP, high-sensitive troponin T (hsTNT), and myocardial wall thickness.It was found that there was a significant increase in VEGFα protein expression (1.66 ± 0.35 vs. 0.62 ± 0.16, p = 0.0009) and a decrease in angiostatin expression (0.024 ± 0.007 vs. 0.053 ± 0.02, p = 0.038) in aortic lysates from α-GAL-Tg/KO compared with that from WT mice. Immunohistochemical staining revealed an adventitial VEGFα signal in α-GAL-Tg/KO mice, whereas no VEGFα signal could be detected in WT mice aortas. No differences in aortic angiostatin expression between α-GAL-Tg/KO- and WT mice could be visualized. The serum levels of VEGFα were significantly upregulated in patients with Fabry’s disease compared with that in healthy controls (708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml, p = 0.048) and positively associated with albuminuria (r = 0.82, p < 0.0001) and elevated NTproBNP (r = 0.87, p < 0.0001) and hsTNT values (r = 0.41, p = 0.048) in male patients with Fabry’s disease. For angiostatin, no significant difference was found between patients with Fabry’s disease and healthy controls (747.6 ± 390.3 vs. 858.8 ± 599.3 pg/ml).In conclusion, an overexpression of VEGFα and downregulation of its counter player angiostatin in aortic tissue of α-GAL-Tg/KO mice support the hypothesis of an underlying vasculopathy in Fabry's disease. Elevated VEGFα serum levels were also observed in patients with Fabry’s disease and were positively associated with elevated markers of organ manifestation in males. These findings suggest that angiogenetic markers, such as VEGFα, may be potentially useful biomarkers for the detection of endothelial dysfunction in classical Fabry's disease.
法布里病是一种 X 连锁溶酶体贮积症,由 α-半乳糖苷酶 A(GAL)活性降低引起,会导致肾脏、心脏和血管器官衰竭而过早死亡。内皮细胞和平滑肌细胞中 GAL 底物葡糖基甘油三酯(Gb3)的积累与早期血管细胞损伤有关,这表明内皮功能障碍是心肾器官衰竭的一个驱动因素。在此,我们研究了法布里α-GAL-Tg/KO小鼠血管中关键血管生成因子VEGFα及其拮抗剂血管抑素的表达,并测定了法布里病患者和健康对照组的循环VEGFα和血管抑素血清水平。通过对石蜡主动脉环进行免疫组化染色来观察 VEGFα 的表达。此外,还采用酶联免疫吸附法测定了 48 名经基因验证的法布里病患者(50% 为男性)和 22 名健康对照者的 VEGFα 和血管生长抑素血清水平,并将其与溶菌酶-Gb3、白蛋白尿、NTproBNP、高敏肌钙蛋白 T(hsTNT)和心肌壁厚度等疾病严重程度指标进行了相关分析。研究发现,与 WT 小鼠相比,α-GAL-Tg/KO 小鼠主动脉裂解物中 VEGFα 蛋白表达量明显增加(1.66 ± 0.35 vs. 0.62 ± 0.16,p = 0.0009),血管抑素表达量减少(0.024 ± 0.007 vs. 0.053 ± 0.02,p = 0.038)。免疫组化染色显示,α-GAL-Tg/KO 小鼠的主动脉内有血管内皮生长因子α信号,而 WT 小鼠的主动脉内检测不到血管内皮生长因子α信号。α-GAL-Tg/KO-小鼠和 WT 小鼠的主动脉血管生成素表达没有差异。与健康对照组相比,法布里病患者血清中的 VEGFα 水平明显升高(708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml,p = 0.048),并与白蛋白尿(r = 0.82,p < 0.0001)和法布里病男性患者的 NTproBNP(r = 0.87,p < 0.0001)和 hsTNT 值升高(r = 0.41,p = 0.048)呈正相关。总之,α-GAL-Tg/KO 小鼠主动脉组织中血管内皮生长因子α的过度表达及其对抗因子血管抑素的下调支持了法布里病潜在血管病变的假说。在法布里病患者血清中也观察到血管内皮生长因子α水平升高,并且与男性器官表现标志物升高呈正相关。这些研究结果表明,血管生成标记物(如 VEGFα)可能是检测典型法布里病内皮功能障碍的潜在有用生物标记物。
{"title":"Overexpression of VEGFα as a biomarker of endothelial dysfunction in aortic tissue of α-GAL-Tg/KO mice and its upregulation in the serum of patients with Fabry’s disease","authors":"N. Lund, H. Wieboldt, L. Fischer, N. Muschol, F. Braun, T. Huber, D. Sorriento, G. Iaccarino, K. Müllerleile, E. Tahir, G. Adam, P. Kirchhof, L. Fabritz, M. Patten","doi":"10.3389/fcvm.2024.1355033","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1355033","url":null,"abstract":"Fabry's disease is an X-linked lysosomal storage disorder caused by reduced activity of α-galactosidase A (GAL), leading to premature death on account of renal, cardiac, and vascular organ failure. Accumulation of the GAL substrate globotriaosylceramide (Gb3) in endothelial and smooth muscle cells is associated with early vascular cell damage, suggesting endothelial dysfunction as a driver of cardiorenal organ failure. Here, we studied the vascular expression of the key angiogenic factors, VEGFα and its antagonist angiostatin, in Fabry α-GAL-Tg/KO mice and determined circulating VEGFα and angiostatin serum levels in patients with Fabry’s disease and healthy controls.Cryopreserved aortic vessels from six α-GAL-Tg/KO and six wild-type (WT) mice were obtained and VEGFα and angiostatin levels were determined by performing Western blot analysis. VEGFα expression was visualized by an immunohistochemical staining of paraffin aortic rings. In addition, VEGFα and angiostatin serum levels were measured by using an enzyme-linked immunosorbent assay in 48 patients with genetically verified Fabry's disease (50% male) and 22 healthy controls and correlated with disease severity markers such as lyso-Gb3, albuminuria, NTproBNP, high-sensitive troponin T (hsTNT), and myocardial wall thickness.It was found that there was a significant increase in VEGFα protein expression (1.66 ± 0.35 vs. 0.62 ± 0.16, p = 0.0009) and a decrease in angiostatin expression (0.024 ± 0.007 vs. 0.053 ± 0.02, p = 0.038) in aortic lysates from α-GAL-Tg/KO compared with that from WT mice. Immunohistochemical staining revealed an adventitial VEGFα signal in α-GAL-Tg/KO mice, whereas no VEGFα signal could be detected in WT mice aortas. No differences in aortic angiostatin expression between α-GAL-Tg/KO- and WT mice could be visualized. The serum levels of VEGFα were significantly upregulated in patients with Fabry’s disease compared with that in healthy controls (708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml, p = 0.048) and positively associated with albuminuria (r = 0.82, p < 0.0001) and elevated NTproBNP (r = 0.87, p < 0.0001) and hsTNT values (r = 0.41, p = 0.048) in male patients with Fabry’s disease. For angiostatin, no significant difference was found between patients with Fabry’s disease and healthy controls (747.6 ± 390.3 vs. 858.8 ± 599.3 pg/ml).In conclusion, an overexpression of VEGFα and downregulation of its counter player angiostatin in aortic tissue of α-GAL-Tg/KO mice support the hypothesis of an underlying vasculopathy in Fabry's disease. Elevated VEGFα serum levels were also observed in patients with Fabry’s disease and were positively associated with elevated markers of organ manifestation in males. These findings suggest that angiogenetic markers, such as VEGFα, may be potentially useful biomarkers for the detection of endothelial dysfunction in classical Fabry's disease.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"90 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139803046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
So close, yet so far away: the relationship between MAM and cardiac disease 如此之近,却又如此之远:MAM 与心脏病之间的关系
Pub Date : 2024-02-05 DOI: 10.3389/fcvm.2024.1353533
Bo Lu, Xiaozhe Chen, Yulong Ma, Mingtai Gui, Lei Yao, Jianhua Li, Mingzhu Wang, Xunjie Zhou, D. Fu
Mitochondria-associated membrane (MAM) serve as crucial contact sites between mitochondria and the endoplasmic reticulum (ER). Recent research has highlighted the significance of MAM, which serve as a platform for various protein molecules, in processes such as calcium signaling, ATP production, mitochondrial structure and function, and autophagy. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health. Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. MAM proteins independently or interact with their counterparts, forming essential tethers between the ER and mitochondria in cardiomyocytes. This review provides an overview of key MAM regulators, detailing their structure and functions. Additionally, it explores the connection between MAM and various cardiac injuries, suggesting that precise genetic, pharmacological, and physical regulation of MAM may be a promising strategy for preventing and treating heart failure.
线粒体相关膜(MAM)是线粒体和内质网(ER)之间的重要接触点。最近的研究突显了线粒体相关膜在钙信号传导、ATP生成、线粒体结构和功能以及自噬等过程中的重要性,因为线粒体相关膜是各种蛋白质分子的平台。任何原因引起的心脏病都会导致心肌结构和功能发生变化,严重影响人类健康。值得注意的是,在肥胖、糖尿病和心脏毒性等几种心脏疾病中,MAM 表现出多种调节作用,以维持细胞平衡。MAM 蛋白独立或与对应蛋白相互作用,在心肌细胞的 ER 和线粒体之间形成重要的纽带。本综述概述了主要的 MAM 调控因子,详细介绍了它们的结构和功能。此外,它还探讨了 MAM 与各种心脏损伤之间的联系,认为对 MAM 进行精确的遗传、药物和物理调控可能是预防和治疗心衰的一种有前途的策略。
{"title":"So close, yet so far away: the relationship between MAM and cardiac disease","authors":"Bo Lu, Xiaozhe Chen, Yulong Ma, Mingtai Gui, Lei Yao, Jianhua Li, Mingzhu Wang, Xunjie Zhou, D. Fu","doi":"10.3389/fcvm.2024.1353533","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1353533","url":null,"abstract":"Mitochondria-associated membrane (MAM) serve as crucial contact sites between mitochondria and the endoplasmic reticulum (ER). Recent research has highlighted the significance of MAM, which serve as a platform for various protein molecules, in processes such as calcium signaling, ATP production, mitochondrial structure and function, and autophagy. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health. Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. MAM proteins independently or interact with their counterparts, forming essential tethers between the ER and mitochondria in cardiomyocytes. This review provides an overview of key MAM regulators, detailing their structure and functions. Additionally, it explores the connection between MAM and various cardiac injuries, suggesting that precise genetic, pharmacological, and physical regulation of MAM may be a promising strategy for preventing and treating heart failure.","PeriodicalId":510752,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"54 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139865791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Cardiovascular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1